As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

The United States Food and Drug Administration (FDA) has suspended Valneva SE’s license for IXCHIQ, citing four new reports ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The FDA suspended the license for vaccine manufacturer Valneva’s chikungunya vaccine following reports of serious adverse events. The decision halts all shipping and sales of the vaccine in the U.S., ...

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...

The Vaccine Adverse Event Reporting System (VAERS), jointly managed by the FDA and the Centers for Disease Control and Prevention (CDC), is gathering and analyzing these cases.